Sign in
WithdrawnPhase 2

Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA

Key facts

Who runs it
Andrew Newberg
Where
Philadelphia, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
8 Jul 2021
Ended
21 Jul 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • [F-18] Fluorodopa Positron Emission Tomography
  • OM Meditation
Record updated
19 September 2025
Why it stopped
funding not obtained

Who can take part

Age
25 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (30)Hide the full registry criteria

Who can take part

  • No clinical diagnosis of PD
  • Age 25 years old and older
  • Physically independent, ambulatory
  • Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception
  • Clinical diagnosis of PD in female partner
  • Age 30 years old and older
  • Physically independent, ambulatory
  • Hoehn and Yahr score of I-III inclusive
  • On stable antiparkinsonian medication for at least one month
  • Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception
  • No clinical diagnosis of PD
  • Age 25 years old and older
  • Physically independent, ambulatory
  • Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception

Who cannot take part

  • Previous brain surgery
  • Subjects with current alcohol or drug abuse
  • Enrollment in active clinical trial/ experimental therapy within the prior 30 days
  • Pending surgery during the course of the study
  • Cancer patients receiving active chemotherapy
  • Cognitive impairment by evaluation or known score on Mini-Mental Status examination of 25 or lower
  • Intracranial abnormalities that may complicate interpretation of the brain scans (e.g., stroke, tumor, vascular abnormality affecting the target area)
  • Diagnosis of traumatic brain injury with significant impairment
  • Any medical disorder or physical condition that could reasonably be expected to interfere with the assessment of parkinsonian syndrome symptoms, or with any of the study assessments including the PET-MRI imaging
  • Subjects with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate
  • History of thrombocytopenia or clotting disorders
  • History of uncontrolled diabetes and/or thyroid conditions
  • History of severe kidney disease (if a subject reports this problem, a serum creatinine will be checked to assess glomerular filtration rate (GFR) and if it is less than 30, they will be excluded)
  • Wheelchair-bound or bed-ridden, non-ambulatory
  • No metal in their body that would prevent MRI scanning (as determined by the PI)
  • Pregnant or lactating women

Where in United States

  • Thomas Jefferson University, Marcus Institute of Integrative Health CentersPhiladelphia, United States

About the trial

What the trial wants to find out

The purpose of this research is to use 18 F Fluorodopa positron emission tomography (FDOPA PET) to measure dopamine function, and utilize magnetic resonance imaging (MRI) to measure inflammatory and oxidative stress markers in persons with Parkinson's disease.

Read full original descriptionShow less

The overall goal of this study will be to further the understanding of the effects of a novel meditation technique called orgasmic meditation (OM) on these neurophysiological parameters.

The 3 groups in the trial

  • Healthy Control Couple PairsExisting treatment, for comparison

    All healthy control subjects, 6 couple pairs (12 subjects) healthy controls in which neither member has Parkinson's Disease will receive a baseline and follow up FDOPA PET scan. All subjects will be asked to complete the surveys. The control group will receive training materials in the practice of OM which the couple will be asked to practice for the next 2-3 months. The couple-pair will begin the OM practice initially (in between the baseline and follow up scans. FDOPA scans and surveys will be conducted with both members of the couple pair at approximately 2-3 months.

    Treatment: OM Meditation

  • Active Couple Pairs Parkinson's GroupExisting treatment, for comparison

    15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD. The female subject will undergo the baseline scan. Both members of the couple will complete surveys. The active group will receive training materials in the practice of OM which they will be asked to practice for the next 2-3 months The active couple-pair will begin the OM practice initially (in between the baseline and follow up). FDOPA scans will be conducted with female members with PD the couple pair at approximately 2-3 months.

    Treatment: [F-18] Fluorodopa Positron Emission Tomography and OM Meditation

  • Waitlist Couple Pairs Parkinson's GroupOther group

    15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD. The female subject will undergo the baseline scan. Both members of the couple will complete surveys The waitlist period in which the female member with PD will continue to receive standard of care for those 2-3 months; who then receive follow up scan. After the follow up scan, the waitlist group may be trained in the practice of OM for the next two months (but there will not be an additional FDOPA scan). Couple-pairs in the waitlist group will be asked to complete surveys at baseline and follow up scan and again after completing the OM Meditation practice. Couple pairs will engage in OM Meditation together approximately 3-4 times a week after the baseline and follow up scans for 2-3 months but female subjects with PD will not receive and additional post OM Meditation FDOPA scan

    Treatment: [F-18] Fluorodopa Positron Emission Tomography

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating the Physiological and Psychological Effects of a Novel Meditation Technique on Cerebral Activity Measured With Functional Magnetic Resonance Imaging(fMRI) and F-18 Fluorodopa PET Imaging
Record updated
19 September 2025